Molecular Partners Ag (MOLN) has released an update.
Molecular Partners AG, a clinical-stage biotech company, is advancing its pipeline with two new programs set to enter clinical trials by 2025, and promising updates on existing programs like MP0533, which shows favorable safety and antitumor activity. The company also expects to be financially stable into 2026, with CHF 174.1 million in cash and short-term deposits, and operating expenses projected to be CHF 70-80 million for 2024. Preclinical and clinical data updates for various innovative therapies, including Radio-DARPin and Switch-DARPin platforms, are anticipated throughout the year.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.
